Investors/Media

Show All

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). The company also plans to evaluate tildacerfont in pediatric classic CAH and polycystic ovary syndrome.

Spruce Biosciences trades on the Nasdaq Global Market under the symbol “SPRB”.

Spruce Biosciences’ headquarters are located at 2001 Junipero Serra Boulevard, Suite 640, Daly City, CA 94014.

The biographies of Spruce Biosciences’ directors are available in the “Board of Directors” section of our company website here.

The biographies of Spruce Biosciences’ management are available in the “Management Team” section of our company website here.

Spruce Biosciences’ fiscal year ends December 31st.

Spruce Biosciences’ independent auditor for the fiscal year ended December 31, 2020 is BDO LLP.

Address:
300 Park Avenue, Suite 900
San Jose, CA 95110

Phone: 408-278-0220

Spruce Biosciences’ outside legal counsel is Cooley LLP.

Address:
101 California Street
5th Floor
San Francisco, CA 94111-5800

Phone: (415) 693-2000

Spruce Biosciences’ quarterly and annual reports and other SEC filings are available by selecting the “SEC Filings” section of our “Investors” page on our company website here, or through SEC’s website here.

Spruce Biosciences’ CUSIP number is 85209E 109.

Computershare
USA +1 (800) 736-3001
(US, Canada, Puerto Rico)
+1 (781) 575 3100 (non-US)
web.queries@computershare.com

Shareholder Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY 40233

Shareholder Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Please see the "Events & Presentations" section of our company website here for a listing of upcoming earnings announcements and other key events.

You can contact Spruce Biosciences’ Investor Relations via email by clicking here.

You can contact Spruce Biosciences’ Media Relations via email by clicking here.

Spruce Biosciences was incorporated in Delaware in April 2016.

If your shares are held in street name (by your broker), you must notify the securities firm holding your stock. If you hold stock certificates in your own name, address changes should be submitted in writing via U.S. mail to our transfer agent, Computershare:

For written requests by regular mail:
Computershare
P.O. Box 505000
Louisville, KY 40233

For written requests by overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202